Mumbai, Oct 13 (UNI) Piramal Life Sciences Limited (PLSL), part of the Piramal Group of companies, today said it has received regulatory approval for the initiation of phase-I study of a new cancer compound P-1446A-05 by Drug Controller General of India (DCGI).
The new cancer compound is an orally active molecule, being developed for the treatment of cancer, for which there are inadequate treatment options. P-1446A-05 is an inhibitor of key enzymes involved in the uncontrolled division and multiplication of cancer cells, the company said in a statement.
Recently, PLSL also received a regulatory approval for the initiation of phase I trial for this compound in Canada. The primary objective of both studies is to identify a safe and tolerable dose to be administered in subsequent phase II trials.
Piramal Group Director Swati Piramal, in the release, said that PLSL aimed to reduce the burden of disease by finding new and affordable cures for unmet medical needs. ''Committed to the Group's values - knowledge, action and care, it focuses upon nurturing innovation and breakthrough thinking to impact the lives of millions, in dynamic, nimble-footed delivery and in making quality drugs accessible,'' she added.
UNI VK RN AK CS1840